Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer

BACKGROUND: Combined therapy of metronomic cyclophosphamide, methotrexate and high-dose celecoxib targeting angiogenesis was used in a phase II trial. METHODS: Patients with advanced cancer received oral cyclophosphamide 50 mg o.d., celecoxib 400 mg b.d. and methotrexate 2.5 mg b.d. for two consecut...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Khan, O A, Blann, A D, Payne, M J, Middleton, M R, Protheroe, A S, Talbot, D C, Taylor, M, Han, C, Patil, M, Harris, A L
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2011
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3111194/
https://ncbi.nlm.nih.gov/pubmed/21587257
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.154
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky